NORWOOD, MA – February 18, 2003 – Cyclis Pharmaceuticals, Inc. today announced publication of laboratory studies demonstrating that an experimental anti-cancer agent, ß-lapachone, can selectively kill ...

ArQule Inc has signed a definitive agreement to acquire Cyclis Pharmaceuticals Inc, a Norwood, Mass., privately-held, cancer therapeutics company. The acquisition is expected to close in August 2003.

Arqule Inc., which has been ramping up its drug-discovery efforts, is acquiring a firm with several promising cancer drugs. The Woburn, Mass.-based company said it is acquiring closely held Cyclis ...

Through its planned $25 million purchase of Cyclis Pharmaceuticals Inc., ArQule Inc. will combine a biology-based program with its chemistry-focused technology to build its own research and ...

Cyclis Pharmaceuticals Inc. is banking on its activated checkpoint therapy to fight cancer. The Norwood, Mass.-based company, founded by CEO Samuel Ackerman and other members of the management team in ...